Status:
COMPLETED
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with ...
Eligibility Criteria
Inclusion
- \- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.
Exclusion
- Previous enrollment in another Allergan Bimatoprost SR Study
- Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
- Anticipated need for laser eye surgery within the first 52 weeks of the study duration
- History of glaucoma surgery
Key Trial Info
Start Date :
December 15 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 22 2020
Estimated Enrollment :
528 Patients enrolled
Trial Details
Trial ID
NCT02250651
Start Date
December 15 2014
End Date
July 22 2020
Last Update
July 28 2021
Active Locations (113)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Center South
Dothan, Alabama, United States, 36301
2
Arizona Eye Center
Chandler, Arizona, United States, 85224
3
Vold Vision
Fayetteville, Arkansas, United States, 72704
4
Mark B. Kislinger, MD, Inc.
Glendora, California, United States, 91741